Rosen Law Firm’s probe into Tandem Diabetes Care (TNDM) after a voluntary correction of certain t:slim X2 insulin pumps, and the roughly 20% share drop that followed, has investors reassessing risk ...

The AID system used in the study is knowns as a Tandem t:slim X2 insulin pump with Control-IQ technology. "We've known for a while that AID systems have achieved better glucose control with less ...

The US Food and Drug Administration (FDA) has granted clearance for the Android version of Tandem Diabetes Care’s Tandem Mobi ...

Patients with type 2 diabetes demonstrated improved glycemic control with the use of automated insulin delivery regardless of baseline C-peptide levels. Automated insulin delivery (AID) systems should ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) ...

Tandem Diabetes Care begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with diabetes ...

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tandem Diabetes Care, Inc. before investing. In this article, we go over a few ...

SAN DIEGO – Tandem Diabetes Care’s Control-IQ+ automated insulin delivery system can lower HbA1c’s in adults with insulin-treated Type 2 diabetes, according to a new study published in the American ...